On Tuesday, Shares of Kohl’s Corporation (NYSE:KSS), gained 0.19% to $47.22.
Kohl’s, declared they are assisting make spirits bright for children in need this holiday with nearly six million dollars in donations to celebrate the season of giving.
On November 23, Kohl’s declared a donation of nearly $5.9 million worth of plush toys and children’s books to the Recently Show’s 22nd annual Holiday Toy Drive. This donation celebrates the company’s largest gift to the Drive since the partnership with the Recently Show began 11 years ago.
New this year, Kohl’s will also support #Giving Tuesday by encouraging customers to join in the giving spirit of the season by purchasing Kohl’s Cares items for only $5 each with 100 percent of net profit benefiting children’s health initiatives nationwide. Available in stores and on Kohls.com, the Kohl’s Cares collection comprises cherished children’s books from author/illustrator Nancy Tillman, coordinating soft toys, a Blake Shelton Christmas CD, a calendar, a note card set and a holiday cookbook. For every Kohl’s Cares purchase made in store or online on Tuesday, December 1, Kohl’s will donate $1 to Toys for Tots, up to $100,000.
Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers.
Shares of Navient Corp (NASDAQ:NAVI), inclined 2.85% to $12.25, during its last trading session.
Navient, declared that President and CEO Jack Remondi and CFO Somsak Chivavibul will speak at the Goldman Sachs U.S. Financial Services Conference on Tuesday, Dec. 8. They will deliver remarks at 9:20 a.m. EST in New York City. A live audio webcast, together with any written materials or slides used during the presentation, will be available at navient.com/investors. A replay will be available about two hours following the presentation through Dec. 22.
Navient Corporation provides financial products and services in the United States. The company operates in four segments: FFELP Loans, Private Education Loans, Business Services, and Other. It provides federal family education loan program (FFELP) loans and servicing for FFELP loan portfolio; and servicing and asset recovery services for loans on behalf of guarantors of FFELP loans, guaranty agencies, higher education institutions, the United States Department of Education, and other federal clients, in addition to states, courts, and municipalities.
Finally, Shares of Clovis Oncology Inc (NASDAQ:CLVS), ended its last trade with 1.91% gain, and closed at $32.05.
The company shares have dropped -35.47% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $116.75 and the one year low was seen on Nov 23, 2015. The 50-Day Moving Average price is $78.57 and the 200 Day Moving Average price is recorded at $85.21.
Clovis Oncology, is predictable to reach $ 76 in the short term. The number of analysts agreeing with this consensus is 4. The higher estimate for the short term price target is at $140 while the lower estimate is at $30. The standard deviation of the price stands at $50.41.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which comprise Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers.